Byron Vaughn

Associate Professor of Medicine, Division of Gastroenterology, Hepatology and Nutrition


Administrator Info
Name: GI Division
Phone: 612-625-8999
Mail: 420 Delaware Street SE, MMC 36, Minneapolis, MN 55455

Dr. Vaughn completed his Internal Medicine residency and Gastroenterology fellowship at Beth-Israel Deaconess Medical Center in Boston. There he developed both clinical and research interests in Inflammatory Bowel Disease. He worked with the IBD Center at BIDMC to study the effect of therapeutic manipulation of the microbiome in Crohn's disease as well as optimizing the management of anti-TNF medications. In addition to his research interests he has worked closely with the medical school teaching students and mentoring physicians in training in clinical and quality improvement research. His main clinical interests include Crohn's disease, Ulcerative Colitis as well as Microscopic colitis and Celiac disease. He also sees patients with recurrent C. difficile colitis. His active areas of research involve clinical trials for IBD.

Research Summary

Dr. Vaughn is actively involved in both clinical and translational research for patient with IBD. The intestinal microbiota has recently been identified as a critical component of many intestinal pathways including immune tolerance and inflammation. Dr. Vaughn is working in collaboration with Dr. Alexander Khoruts to continue to understand how the microbiota functions to induce inflammation or tolerance. Additionally, Dr. Vaughn has been a strong proponent for therapeutic drug monitoring. This includes monitoring drug levels for patient on anti-TNFs such as infliximab and adalimumab. His research demonstrates that by close monitoring of these medication and titration to a therapeutic window, patients have more effective disease control and less chance of developing anti-drug antibodies.He continues to study the effect of therapeutic drug monitoring on antibody development.

Clinical Summary

Inflammatory Bowel Disease; Clinical trials in IBD; Crohn's Disease; Ulcerative Colitis; Microscopic colitis


MD, Drexel University

Fellowships, Residencies, and Visiting Engagements

Internal Medicine,
Beth-Israel Deaconess Medical Center
Gastroenterology, Fellowship
Beth-Isreal Deaconess Medical Center

Honors and Recognition

Educational Excellence, University of Minnesota
Clinical Excellence, University of Minnesota
50 Most Influential Volunteers, Crohn’s & Colitis Foundation, Minnesota/Dakotas Chapter
Teacher of the Year, University of Minnesota Gastroenterology Fellowship
Top Doctors, Minnesota Monthly Magazine (2017, 2021)
Top Doctor - Rising Star, Mpls. St.Paul Magazine (2017, 2018, 2019)

Professional Memberships

Crohn's and Colitis Foundation, Member
American Gastroenterological Association, Member
AGA Academy of Educators, Member
American College of Gastroenterology, Member
Selected Publications

Selected Publications

Rajasingham R, Enns EA, Khoruts A, Vaughn BP. Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines. Clin Infect Dis. 2020 Feb 14;70(5):754-762. doi: 10.1093/cid/ciz318. PMID: 31001619; PMCID: PMC7319265.,
Negoescu DM, Enns EA, Swanhorst B, Baumgartner B, Campbell JP, Osterman MT, Papamichael K, Cheifetz AS, Vaughn BP. Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflamm Bowel Dis. 2020 Jan 1;26(1):103-111. doi: 10.1093/ibd/izz113. PMID: 31184366; PMCID: PMC6905301.,
Aby ES, Lake JR, Vaughn BP. The Impact of Biologics for the Management of Inflammatory Bowel Disease on Liver Enzymes. Clin Liver Dis (Hoboken). 2020 Dec 10;16(5):212-217. doi: 10.1002/cld.1005. PMID: 33318791; PMCID: PMC7727846.,
Vaughn BP, Yarur AJ, Graziano E, Campbell JP, Bhattacharya A, Lee JY, Gheysens K, Papamichael K, Osterman MT, Cheifetz AS, Cross RK. Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease. J Clin Med. 2020 Sep 28;9(10):3142. doi: 10.3390/jcm9103142. PMID: 32998473; PMCID: PMC7601452.,
Jasurda JS, McCabe RP, Vaughn BP. Adalimumab Concentration Changes Following Dose Escalation in Inflammatory Bowel Disease. Ther Drug Monit. 2020 Dec 17;Publish Ahead of Print. doi: 10.1097/FTD.0000000000000849. Epub ahead of print. PMID: 33346627.,